{
    "info": {
        "nct_id": "NCT05342584",
        "official_title": "Phase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cytarabine Followed by High-Dose Cytarabine in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome",
        "inclusion_criteria": "* New diagnosis of AML by WHO criteria. Patients with higher risk MDS (R-IPSS>3.5) and 10% blasts or more, or proliferative (WBC ≥ 13 x 10⁹/L) CMML-2 are also eligible at the discretion of the PI. Patients having received any prior hypomethylating agent with or without BCL2 inhibitor therapy for MDS/AML are also eligible at the discretion of the PI\n* Patients ≥ 18 to ≤ 75 years.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2\n* Adequate renal function including creatinine clearance > 30 mL/min based on the Cockcroft Gault equation.\n* Adequate hepatic function including total bilirubin < 1.5x ULN unless increase is due to Gilbert's disease or leukemic involvement, and AST and/or ALT < 3x ULN unless considered due to leukemic involvement\n* Ability to understand and provide signed informed consent\n* Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
        "exclusion_criteria": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML)\n* Subject has known active CNS involvement with AML\n* Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <45% by echocardiogram or multi-gated acquisition (MUGA) scan\n* Patients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias\n* Patients with uncontrolled infection with human immunodeficiency virus (HIV) or active Hepatitis B or C\n* Patients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally.\n* Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study.\n* Subject has a white blood cell count > 25 x 10⁹/L. (Note: Hydroxyurea and/or cytarabine (1 or 2 doses; up to 2 is permitted to meet this criterion.)\n* Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception. Appropriate method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate hepatic function including total bilirubin < 1.5x ULN unless increase is due to Gilbert's disease or leukemic involvement, and AST and/or ALT < 3x ULN unless considered due to leukemic involvement",
            "criterions": [
                {
                    "exact_snippets": "total bilirubin < 1.5x ULN unless increase is due to Gilbert's disease or leukemic involvement",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "Gilbert's disease",
                                "leukemic involvement"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and/or ALT < 3x ULN unless considered due to leukemic involvement",
                    "criterion": "AST and/or ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "leukemic involvement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients ≥ 18 to ≤ 75 years.",
            "criterions": [
                {
                    "exact_snippets": "Patients ≥ 18 to ≤ 75 years.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 75,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function including creatinine clearance > 30 mL/min based on the Cockcroft Gault equation.",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance > 30 mL/min based on the Cockcroft Gault equation",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and provide signed informed consent",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "comprehension",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provide signed informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New diagnosis of AML by WHO criteria. Patients with higher risk MDS (R-IPSS>3.5) and 10% blasts or more, or proliferative (WBC ≥ 13 x 10⁹/L) CMML-2 are also eligible at the discretion of the PI. Patients having received any prior hypomethylating agent with or without BCL2 inhibitor therapy for MDS/AML are also eligible at the discretion of the PI",
            "criterions": [
                {
                    "exact_snippets": "New diagnosis of AML by WHO criteria",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "new"
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "WHO criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "higher risk MDS (R-IPSS>3.5) and 10% blasts or more",
                    "criterion": "myelodysplastic syndrome (MDS) risk and blast percentage",
                    "requirements": [
                        {
                            "requirement_type": "risk_score",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.5,
                                "unit": "R-IPSS"
                            }
                        },
                        {
                            "requirement_type": "blast_percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "proliferative (WBC ≥ 13 x 10⁹/L) CMML-2",
                    "criterion": "chronic myelomonocytic leukemia (CMML-2) with proliferative WBC",
                    "requirements": [
                        {
                            "requirement_type": "WBC_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 13,
                                "unit": "x 10⁹/L"
                            }
                        },
                        {
                            "requirement_type": "CMML_subtype",
                            "expected_value": "CMML-2"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients having received any prior hypomethylating agent with or without BCL2 inhibitor therapy for MDS/AML",
                    "criterion": "prior therapy for MDS/AML",
                    "requirements": [
                        {
                            "requirement_type": "prior_therapy",
                            "expected_value": [
                                "hypomethylating agent",
                                "BCL2 inhibitor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 75 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 75 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study.",
            "criterions": [
                {
                    "exact_snippets": "any other significant medical or psychiatric history",
                    "criterion": "significant medical or psychiatric history",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator would adversely affect participation in this study",
                    "criterion": "adverse effect on study participation (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment of adverse effect",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally.",
            "criterions": [
                {
                    "exact_snippets": "known dysphagia",
                    "criterion": "dysphagia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "short-gut syndrome",
                    "criterion": "short-gut syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally",
                    "criterion": "conditions affecting oral drug ingestion or gastrointestinal absorption",
                    "requirements": [
                        {
                            "requirement_type": "effect on ingestion or gastrointestinal absorption of orally administered drugs",
                            "expected_value": "would affect"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML)",
            "criterions": [
                {
                    "exact_snippets": "Patients with t(15;17) karyotypic abnormality",
                    "criterion": "t(15;17) karyotypic abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute promyelocytic leukemia (FAB class M3-AML)",
                    "criterion": "acute promyelocytic leukemia (FAB class M3-AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias",
            "criterions": [
                {
                    "exact_snippets": "history of myocardial infarction within the last 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable / uncontrolled angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of severe and/or uncontrolled ventricular arrhythmias",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has known active CNS involvement with AML",
            "criterions": [
                {
                    "exact_snippets": "known active CNS involvement with AML",
                    "criterion": "CNS involvement with AML",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <45% by echocardiogram or multi-gated acquisition (MUGA) scan",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association (NYHA) Class III or IV congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF <45% by echocardiogram or multi-gated acquisition (MUGA) scan",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has a white blood cell count > 25 x 10⁹/L. (Note: Hydroxyurea and/or cytarabine (1 or 2 doses; up to 2 is permitted to meet this criterion.)",
            "criterions": [
                {
                    "exact_snippets": "white blood cell count > 25 x 10⁹/L",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "x 10⁹/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception. Appropriate method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide).",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential (WOCBP) with positive urine pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "urine pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential who are not willing to maintain adequate contraception",
                    "criterion": "contraception willingness",
                    "requirements": [
                        {
                            "requirement_type": "willingness to maintain adequate contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Appropriate method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide)",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "method of contraception",
                            "expected_value": [
                                "oral hormonal birth control",
                                "injectable hormonal birth control",
                                "IUD",
                                "double barrier methods (e.g., condom with spermicide)"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Male subjects must agree to refrain from unprotected sex from initial study drug administration until 90 days after the last dose of study drug.",
                    "criterion": "unprotected sex",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from unprotected sex",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from initial study drug administration"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after the last dose of study drug"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Male subjects must agree to refrain from ... sperm donation from initial study drug administration until 90 days after the last dose of study drug.",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from sperm donation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from initial study drug administration"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after the last dose of study drug"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Patients with uncontrolled infection with human immunodeficiency virus (HIV) or active Hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled infection with human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "active Hepatitis B",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active Hepatitis C",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}